ClinicalTrials.gg
CompletedNCT05266261Updated Mar 4, 2022

Use of Ibandronate in Diabetic Patients

An interventional study of Ibandronate Oral Tablet in Osteoporosis, Postmenopausal and Type 2 Diabetes, sponsored by Yeouido St. Mary's Hospital. Completed at 1 site in Korea, Republic of. Open to female participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2022-03-04.

Sponsored by Yeouido St. Mary's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Oct 2018, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
121
Allocation
Non-randomized
Ages
55 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies testing Ibandronic Acid in Osteoporosis, Postmenopausal — 1 open to participants now, 1 under way, none of them phase 3. Ibandronic Acid · Osteoporosis, Postmenopausal.

Enrollment
20th of 25
121 · median 410
Started
2018
the only one that year
No phase
Only one
of the 25
Registered
24th of 25
by date
Lead sponsor
1 of 25
Yeouido St. Mary's Hospital

Among the 25 studies testing Ibandronic Acid in Osteoporosis, Postmenopausal, this one is the 20th largest by enrollment, is the only one that started in 2018, is the only one with no phase, and was the 24th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 25 studies testing Ibandronic Acid in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Ibandronic Acid

Ibandronic Acid: first FDA approval 2003 (BONIVA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Ibandronic Acid in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

The purpose of this study is to examine whether monthly oral administration of ibandronate to postmenopausal osteoporosis patients with type 2 diabetes differs in safety and efficacy compared to patients without diabetes.

Read the detailed description

There are two major considerations in the use of bisphosphonates in diabetic patients.

  • The low rate of bone turnover in diabetic patients is at risk of side effects such as excessive inhibition of bone turnover associated with the use of bisphosphonates.
  • A decrease in osteocalcin following bisphosphonate use may lead to deterioration of glucose metabolism.

The efficacy of ibandronate in T2DM is not thought to be significantly different based on previous studies, but there is few study on ibandronate.

03

Conditions studied

  • Osteoporosis, Postmenopausal
  • Type 2 Diabetes
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age of at least 55 years at the time of screening
  • woman
  • diagnosis of osteoporosis

Exclusion criteria

Exclusion Criteria:

  • history of osteoporosis treatment
  • underlying disease (e.g., heart failure, liver disease, renal disease, or )
  • the use of drugs that affect bone metabolism (e.g., , , gonadotropin-releasing hormone agonists, aromatase inhibitors, thiazolidinedione drugs, anticonvulsants, and antidepressants)
  • history of adverse effects of bisphosphonate or difficulty taking the drug due to an inability to sit or the presence of upper gastrointestinal disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Active comparator
    Non-diabetes

    postmenopausal women with normal glucose tolerance

    Drug: Ibandronate Oral Tablet

  • Experimental
    diabetes

    postmenopausal women with type 2 diabetes

    Drug: Ibandronate Oral Tablet

Interventions

  • DrugIbandronic AcidStudies of Ibandronic AcidIbandronic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    150 mg of ibandronate + 24,000 IU of cholecalciferol

    Also known as: daily oral formulation of 1,250 mg of calcium carbonate + 1,000 IU of cholecalciferol

06

What researchers measure

Primary outcomes

  1. Bone mineral density

    . Percentage change in dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck, presented as least square mean and 95% confidence interval.

    Time frame: 1 year

Secondary outcomes

  1. Bone turnover markers

    Percentage change in bone turnover markers \[Serum C-telopeptide (CTx) and procollagen type 1 N-terminal propeptide (P1NP) levels were measured by immunoassay methods using Elecsys kits - 07296355001V4 and 07296509001V4 (Roche Diagnostic Corp., Basel, Switzerland) \] presented as adjusted mean and 95% confidence interval using the generalized estimating equations for repeated measures analysis.

    Time frame: 6 month and 12 month

07

Study locations

1 site
  • Yeouido St.Mary's Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Kim J, Kim KM, Lim S, Kang MI, Baek KH, Min YK. Efficacy of bisphosphonate therapy on postmenopausal osteoporotic women with and without diabetes: a prospective trial. BMC Endocr Disord. 2022 Apr 11;22(1):99. doi: 10.1186/s12902-022-01010-w. PubMed 35410197 ↗

Individual participant data

Plan to share: No — The data that support the findings of this study are available from the corresponding author upon reasonable request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Aug 2021, 34 months.

Of 48 non-industry interventional studies with no phase under Osteoporosis, Postmenopausal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's 34 months is above that.

Counting every sponsor, half of 51 studies reached it within 17 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2022
First posted
Mar 4, 2022
StartActual
Oct 1, 2018
Primary completionActual
Aug 30, 2021
CompletionActual
Jan 31, 2022
Last update
Mar 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05266261
Lead sponsor
Yeouido St. Mary's Hospital
Responsible party
Sponsor
First posted
Mar 4, 2022
Start date
Oct 1, 2018
Primary completion
Aug 30, 2021
Completion
Jan 31, 2022
Last update
Mar 4, 2022

Study contacts

Ki-Hyun Baek, M.D., Ph.D.
principal investigator · Yeouido St. Mary's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibandronic Acid

Start the discussion